GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

Shares rose after strong clinical data strengthened the case for its $10.6 billion Nuvalent acquisition and broader push to rebuild oncology around lung cancer.

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

GSK PLC GSK +1.87% shares rose 4.74% to £18.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX -0.28% rising 0.44% to 10,697.57.

GSK stock increased 0.4% following Berenberg's upgrade to buy with £22 target and announcement of $750M Chimagen deal for multiple myeloma therapy.

GSK shares climbed after the company reported encouraging clinical trial results for two lung cancer treatments, strengthening its oncology strategy despite mixed analyst views on the stock.

GSK (GSK) shares clocked seven straight sessions of gains, as the stock rose 1.7% at $60.19 on Friday. The multinational healthcare giant gained 16.8% in the preceding six sessions. The stock has ...

GSK stock in London traded around 1,858.5 pence on September 15, 2026 after the company agreed a deal worth up to USD 750 million for a blood cancer drug. Berenberg raised its rating to Buy and lifted ...

Pharma giant GSK (NYSE:GSK) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Pharma giant GSK (NYSE:GSK) made a move to enter the weight loss market earlier this year after it ...

Harvey Jones backed the GSK share price to spring into life a couple of years ago, but it's still struggling to make headway. Why isn't it doing better? The post Trading below levels seen 25 years ago ...

GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen ...